Cancer biotech Cerulean Pharma sets terms for $60 million IPO

By
A A A

Cerulean Pharma, a clinical-stage biotech developing targeted cancer therapies for liver and ovarian cancer, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $60 million by offering 5.0 million shares at a price range of $11 to $13. At the midpoint of the proposed range, Cerulean would command a fully diluted market value of $180 million.

Cerulean Pharma, which was founded in 2005, plans to list on the NASDAQ under the symbol CERU. It initially filed confidentially on January 30, 2014. Leerink Partners is the sole bookrunner on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CERU

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

183,639,073
  • $42.32 ▲ 3.85%
82,623,623
  • $15.99 ▼ 22.79%
39,547,942
  • $119 ▲ 1.19%
32,107,751
  • $77.62 ▲ 2.63%
29,684,848
  • $10.60 ▲ 2.02%
27,615,309
  • $24.03 ▲ 0.38%
26,917,669
  • $31.10 ▲ 2.07%
26,464,306
  • $47.75 ▲ 0.59%
As of 11/26/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com